Coleman M, Sobel S, Bhagavan H N, Coursin D, Marquardt A, Guay M, Hunt C
J Ment Defic Res. 1985 Sep;29 ( Pt 3):233-40. doi: 10.1111/j.1365-2788.1985.tb00333.x.
Nineteen patients with Down's syndrome participated in a double blind study of the clinical effects of pharmacological doses of vitamin B6 administration, starting under 8 weeks of age and continuing until 3 years of age. Ten patients received the vitamin and nine the placebo. In Part 1 of this study, no statistically significant differences were found between the two groups in mental age, height, weight, cranial circumference or tongue protrusion. A study of side effects conducted on a larger open population found vitamin B6 to be relatively safe when administered over long periods of time with photosensitive blisters as the major complication.
19名唐氏综合征患者参与了一项双盲研究，研究从8周龄以下开始，持续至3岁，给予药理剂量的维生素B6，观察其临床效果。10名患者接受维生素治疗，9名患者接受安慰剂治疗。在本研究的第一部分中，两组在智力年龄、身高、体重、头围或伸舌方面未发现统计学上的显著差异。在更大规模的开放人群中进行的副作用研究发现，长时间服用维生素B6相对安全，主要并发症为光敏性水泡。
